See the DrugPatentWatch profile for rasuvo
How Rasuvo Delivers Methotrexate Differently
Rasuvo is a subcutaneous auto-injector form of methotrexate, administered by injection under the skin, while oral methotrexate comes as tablets taken by mouth. The injection bypasses the digestive system, leading to more consistent absorption—especially useful for patients with gastrointestinal issues or nausea that impair oral uptake.[1]
Why Absorption Matters: Bioavailability Comparison
Oral methotrexate has variable bioavailability (around 20-40% in low doses, dropping lower at higher doses due to first-pass metabolism in the liver). Rasuvo achieves near 100% bioavailability because it enters the bloodstream directly, providing predictable blood levels. This reduces "hit-or-miss" dosing common with pills.[1][2]
Dosing Schedules and Strengths
Rasuvo offers single-use prefilled syringes in strengths from 7.5 mg to 30 mg, dosed weekly for rheumatoid arthritis, psoriasis, or polyarticular juvenile idiopathic arthritis. Oral methotrexate is typically 7.5-25 mg weekly, split into multiple tablets. Rasuvo simplifies high-dose weeks without pill counting.[1]
Who Benefits Most from Rasuvo Over Pills
Patients with poor oral tolerance—like those with vomiting, Crohn's disease, or inconsistent absorption—see better efficacy with Rasuvo. Studies show it matches oral exposure at equivalent doses but with less variability, improving symptom control in rheumatoid arthritis.[2][3]
Common Side Effects: Injection vs. Oral
Both forms share methotrexate risks like nausea, fatigue, liver enzyme elevation, and infection susceptibility. Rasuvo adds minor injection-site reactions (redness, pain in <10% of cases), but skips oral-specific gut upset. Monitoring (blood tests every 1-3 months) is identical.[1][4]
Cost and Access Differences
Rasuvo costs $500-1,000 per monthly dose (with copay cards often reducing to $5-25), higher than generic oral methotrexate ($10-50/month). Insurance often covers both, but Rasuvo requires prior authorization for "medical necessity" like absorption failure.[1]
Sources
[1]: Rasuvo Prescribing Information (FDA)
[2]: DrugPatentWatch.com - Rasuvo vs. Methotrexate Comparisons
[3]: Clinical Pharmacology Study (J Rheumatol, 2018)
[4]: Medscape - Methotrexate Formulations